Exact Sciences
EXAS
$64.98
Share price
-0.94%
Change (1 day)
36.55%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Exact Sciences (EXAS) - Total debt
Total debt on the balance sheet as of June 2023 : $2.48 B
According to Exact Sciences's latest financial reports the company's total debt is $2.48 B. A company’s total debt is the sum of all current and non-current debts.
Exact Sciences - Total debt on balance sheet (from 2009 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $2.41 B | 2.38% |
| 2021-12-31 | $2.36 B | 61.35% |
| 2020-12-31 | $1.46 B | 54.73% |
| 2019-12-31 | $0.94 B | 37.38% |
| 2018-12-31 | $0.68 B | 16035.44% |
| 2017-12-31 | $4.26 M | -7.86% |
| 2016-12-31 | $4.63 M | -4.51% |
| 2015-12-31 | $4.85 M | 385.2% |
| 2014-12-31 | $1 M | -26.47% |
| 2013-12-31 | $1.36 M | -20.51% |
| 2012-12-31 | $1.71 M | 71.1% |
| 2011-12-31 | $1 M | 0% |
| 2010-12-31 | $1 M | 0% |
| 2009-12-31 | $1 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $22.85 B | 821.43% | 🇫🇷 France |
 Veracyte VCYT | $14.86 M | -99.40% | 🇺🇸 USA |
 Antares Pharma ATRS | N/A | N/A | 🇺🇸 USA |
 Myriad Genetics MYGN | $0.20 B | -91.78% | 🇺🇸 USA |
 Biocept
BIOC | $11.59 M | -99.53% | 🇺🇸 USA |